Introduction {#sec1_1}
============

Hepatitis C virus (HCV) infection is a major health problem with 185 million people chronically infected worldwide \[[@B1]\]. In Japan, about 1.5 million people are chronically infected with HCV \[[@B2]\]. HCV and hepatitis B virus infection are the leading causes of cirrhosis, hepatocellular carcinoma (HCC), and liver transplantation worldwide. Until recently, interferon (IFN) treatment was the standard therapy for the eradication of HCV \[[@B3], [@B4]\]. Lately, IFN-free direct-acting antivirals (DAA) with high sustained virological response (SVR) rates and few side effects have changed the treatment of hepatitis C markedly \[[@B5], [@B6], [@B7]\].

HCV causes not only liver disease but also disorders of other organs and tissues \[[@B8]\]. Several extrahepatic manifestations have been reported. Lichen planus (LP) is one such extrahepatic manifestation of HCV infection \[[@B9], [@B10]\]. LP is a chronic inflammatory disease that can affect the skin and any lining mucosa. Oral lichen planus (OLP) mostly affects middle-aged and older females. Epidemiologic studies have shown that OLP develops in approximately 10--20% of Japanese individuals with HCV infection in northern Kyushu \[[@B11], [@B12], [@B13]\] and Hiroshima prefecture \[[@B14], [@B15]\]. While the mechanism of HCV-related LP is not known, we identified SNPs for LP in a genome-wide association study (GWAS) of Japanese patients with HCV infection \[[@B16]\].

We have previously reported the successful use of IFN-free DAAs in patients with HCV-associated OLP \[[@B17], [@B18]\]. Herein, we report a case of OLP accompanied by HCV-related HCC that disappeared after liver transplantation and achievement of SVR, following IFN-free DAA.

Case Presentation {#sec1_2}
=================

In June 2008, a 53-year-old Japanese male presented to the Kurume University Hospital (Fukuoka, Japan) with a burning pain in the lower lip when eating and drinking (Fig. [1a](#F1){ref-type="fig"}). The oral lesion was diagnosed pathologically as OLP.

Concerning his history according to the medical record of Nakasonekazu Medical Clinic (Okinawa, Japan), which is a family doctors' practice, he was diagnosed with chronic hepatitis C at the age of 42 years (in 1996) and received IFNα2b at a dose of 6 million units/day 3 times a week for 24 weeks. However, he did not achieve SVR. In April 2002, the 47-year-old patient was treated with IFNα2b and ribavirin (RBV) at a dose of 800 mg/day. In April 2005, the 50-year-old patient was treated with pegylated interferon (Peg-IFN)α2b, 120 μg/week, and RBV at a dose of 1,000 mg/day. In July 2005, he developed a refractory lesion (considered to be OLP) of the lower lip as a side effect of IFN therapy. The schedule of his treatment for chronic hepatitis C was as follows: self-administration of IFN alfacon-1 at 51 years of age, Peg-IFNα2b and RBV at 51 years, and Peg-IFNα2a at 53 years (Fig. [2](#F2){ref-type="fig"}). In June 2006, he developed hyperthyroidism as a side effect of IFN therapy. The lesion of the lower lip worsened each time he received IFN therapy. Therefore, the IFN treatment was stopped because of pain and bleeding from the exacerbation of refractory cheilitis and, consequently, he did not achieve SVR.

There was no history of blood transfusion or tattooing and his family history was not contributory. The laboratory data at his first visit for examination of oral membrane disease in 2008 were AST 71 U/L, ALT 87 U/L, HCV RNA concentration 6.8 logIU/mL, genotype 1b, *IL28B* (also known as *IFNL3*) nonTT, wild-type aa 70 and non-wild-type aa 91 in the HCV core region, number of ISDR mutations zero, and negative results for HBsAg (Table [1](#T1){ref-type="table"}). We performed a GWAS to identify genetic variants associated with HCV-related OLP \[[@B16]\]. In our previous report, we identified novel associations of rs884000 in neuropilin-2 (*NRP2*), rs538399 on insulin-like growth binding proteins factor 4 (*IGFBP4*), and supported the association of the *HLA-DR/DQ* genes, with HCV-positive LP in the Japanese and Italian population. This patient had no risk allele (TT) at rs884000 in *NRP2* and no resistance allele (TT) at rs538399 in *IGFBP4*. The patient underwent ultrasonographic examination and computed tomography. Alternative potential predictors of progression of liver cirrhosis were applied. The patient was diagnosed with liver cirrhosis. The erosive OLP lesion was not widely aggravated by the application of steroids (Dexaltin Oral Ointment®; Nippon Kayaku Co. Ltd., Tokyo, Japan) and glycyrrhizin (Stronger Neo-Minophagen C®; Minophagen Pharmaceutical Co. Ltd., Tokyo, Japan).

In July 2010, the 55-year-old patient developed OLP at the bilateral buccal mucosas other than the lower lip (Fig. [1b](#F1){ref-type="fig"}) and received surgical hepatic resection and percutaneous radiofrequency ablation for the treatment of HCC. The schedule of his treatment for recurrent HCC was as follows: percutaneous radiofrequency ablation in September 2012, radiofrequency ablation in March 2013, transcatheter arterial chemoembolization in March 2014, and liver transplantation from a living donor in March 2015. The symptom of OLP did not become aggravated. Treatment with immunosuppressive agents, tacrolimus (Prograf®), mycophenolate mofetil (CellCept®), and prednisolone, and antiviral agents, entecavir (Baraclude®) as prophylaxis therapy against hepatitis B virus reactivation \[[@B19]\], was started. Table [1](#T1){ref-type="table"} and Figure [2](#F2){ref-type="fig"} show the results of the clinical examinations.

He received DAA treatment involving a 12-week course of ledipasvir (LDV) 90 mg and sofosbuvir (SOF) 400 mg (Harvoni®; Gilead Sciences Inc., Foster City, CA, USA) from February 29, 2016, until May 23, 2016, at the Ryukyu University Hospital (Okinawa, Japan) and SVR was achieved. The OLP lesion was not aggravated during the DAA therapy. After DAA therapy (SVR24), the OLP of the lower lip and buccal mucosal had disappeared (Fig. [1c, d](#F1){ref-type="fig"}). Clinical examination after 8 years and 5 months (December 3, 2016) revealed the presence of an asymptomatic pigmented lesion on the lower lip that was not present at the first evaluation.

Discussion {#sec1_3}
==========

Several studies have confirmed that HCV infection is an important correlate in patients with OLP, especially in Japan and Italy. Recently, we identified SNPs for LP in a GWAS of Japanese patients with HCV infection \[[@B16]\]. The GWAS has become a powerful tool for investigating the genetic basis of various diseases. Our GWAS supports the association of previously reported *HLA-DR/DQ* genes (rs9461799) and newly suggests that the *NRP2* and *IGFBP4* loci are associated with HCV-related LP susceptibility. We found 2 SNPs (rs884000 in the *NRP2* locus and rs538399 in the *IGFBP4 locus*). The odds ratios of minor alleles (95% confidence interval) of rs884000, rs538399, and rs9461799 were 3.25 (1.95--5.41), 0.40 (0.25--0.63), and 2.15 (1.41--3.28), respectively. This case did not have the risk allele at rs884000 in *NRP2* or no resistance allele at rs538399 in *IGFBP4*.

Erosive OLP is painful and interferes with the normal daily activities of the patient, including eating, drinking, and speaking. The symptoms of HCV-associated OLP are often exacerbated following IFN therapy \[[@B20], [@B21], [@B22]\]. Therefore, until now, it has been important to predict the onset and exacerbation of OLP and determine an appropriate period of therapeutic intervention. This case was not able to complete treatment because of exacerbation of OLP, regardless of many types and doses of IFN therapy.

The glycyrrhizin used for this patient was useful as anti-inflammatory treatment of OLP, as we reported previously \[[@B23], [@B24]\]. However, the use of glycyrrhizin is not a radical treatment of OLP, because OLP relapses when administration of glycyrrhizin is stopped.

The recently developed series of DAAs has greatly improved the treatment outcome of patients with HCV infection. A Japanese phase 3 trial included 341 treatment-naïve and treatment-experienced patients who were randomized to receive LDV/SOF for 12 weeks (group I, 171 patients) or LDV/SOF plus RBV for 12 weeks (group II, 170 patients) \[[@B7]\]. SVR12 was achieved by 171 (100%) patients (83/83 treatment-naïve and 88/88 treatment-experienced patients) who received LDV/SOF and 167/170 (98%) patients (80/83 treatment-naïve and 87/87 treatment-experienced patients) who received LDV/SOF plus RBV. Antiviral treatment resulting in viral eradication is the only way to improve liver transplant patient and graft survival. The use of second-generation DAAs in transplant patients was reported to achieve better efficacy \[[@B25]\].

There are a few reports about IFN-free DAA treatment of HCV-associated extrahepatic manifestations, including OLP, mixed cryoglobulinemia, and rheumatic diseases \[[@B17], [@B18], [@B26], [@B27]\]. We have previously reported the outcomes of HCV-associated OLP in patients who received successful treatment with IFN-free DAAs, using the daclatasvir plus asunaprevir combination therapy \[[@B17], [@B18]\]. The symptoms of OLP subsided in all patients. Yoshikawa et al. \[[@B28]\] reported successful SOF and RBV treatment for genotype 2 HCV infection with compensated cirrhosis and OLP.

This is a case report of HCV-related OLP after liver transplantation, with successful IFN-free treatment with LDV/SOF. A follow-up visit in December 2016, 8 years and 5 months after the patient\'s first visit, disclosed the presence of a dark brown-pigmented alteration of his oral mucosa. The pathogenesis of oral postinflammatory pigmentation has rarely been investigated. Mergoni et al. \[[@B29]\] reported a clinicopathological evaluation of oral postinflammatory pigmentation, with a discussion of its possible etiopathogenesis and diagnosis. Melanocytes are cells that produce melanin, a dark brown pigment responsible for the color of the skin, and also participate in the inflammatory response. Melanocytes have been found to be the source of and responsive to a variety of inflammatory mediators \[[@B30]\].

The effects of immunosuppressive agents, such as tacrolimus and mycophenolate mofetil, on the severity and progression of OLP have been reported \[[@B31], [@B32]\]. Tacrolimus inhibits the activation and proliferation of T-lymphocytes by inhibiting the phosphatase activity of calcineurin and mycophenolate mofetil inhibits lymphocyte proliferation and activation. Immunosuppressive therapy following liver transplantation for HCC may have led to the disappearance of the OLP lesion in our patient, as in previous reports \[[@B33], [@B34]\]. We reported a case of OLP accompanied by primary biliary cirrhosis that disappeared after liver transplantation and immunosuppressive drug therapy \[[@B34]\].

In conclusion, the patient with HCV-associated OLP in this case study was treated using IFN-free DAAs, which led to disappearance of the symptoms of OLP. This is the first report of LDV/SOF administered for genotype 1 HCV-associated OLP. Long-term follow-up is needed to elucidate the therapeutic effects of transplantation.
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![**a** Erosive oral lichen planus (OLP) lesions affecting the lower lip of the 53-year-old male at his first visit to Kurume University Hospital (June 2008). **b** Bilateral buccal mucosa OLP onset in the 55-year-old male (July 2010). **c** Disappearance of OLP showing postinflammatory melanin pigmentation in the lower lip (December 2016). **d** Disappearance of OLP showing postinflammatory melanin pigmentation in the buccal mucosa (December 2016).](crg-0011-0701-g01){#F1}

![Clinical course of the patient. The black illustration on the top shows the severity of the symptoms of oral lichen planus (OLP). RFA, radiofrequency ablation; PRFA, percutaneous radiofrequency ablation; TACE, transcatheter arterial chemoembolization.](crg-0011-0701-g02){#F2}

###### 

Summary of the clinical condition of oral lesion and laboratory data

                              Normal range   First visit to examine oral lesions   Follow-up of oral lesions     Admission for recurrent HCC   Before liver transplantation   Liver transplantation         After liver transplantation   Before DAA treatment          Start of DAA treatment   SVR12               SVR24
  --------------------------- -------------- ------------------------------------- ----------------------------- ----------------------------- ------------------------------ ----------------------------- ----------------------------- ----------------------------- ------------------------ ------------------- -------------------
  Date                                       Jul. 17, 2008                         Jul. 10, 2010                 Aug. 7, 2014                  Jan. 14, 2015                  Mar. 10, 2015                 Jun. 3, 2015                  Feb. 15, 2016                 Feb. 29, 2016            Aug. 16, 2016       Nov. 7, 2016
                                                                                                                                                                                                                                                                                                                     
  Age, years                                 53                                    55                            59                            60                             60                            60                            61                            61                       61                  61
                                                                                                                                                                                                                                                                                                                     
  Clinical condition of OLP                  Presence                              Exacerbation                  Presence                      Presence                       Presence                      Improvement                   Improvement                                            Disappearance       Disappearance
                                                                                                                                                                                                                                                                                                                     
  Sites of OLP                               Lower lip                             Lower lip and buccal mucosa   Lower lip and buccal mucosa   Lower lip and buccal mucosa    Lower lip and buccal mucosa   Lower lip and buccal mucosa   Lower lip and buccal mucosa                            OLP disappearance   OLP disappearance
                                                                                                                                                                                                                                                                                                                     
  **Laboratory data**                                                                                                                                                                                                                                                                                                
  AST, U/L                    13--33         71                                    50                            36                            35                                                           14                            28                                                     21                  21
  ALT, U/L                    6--30          87                                    58                            43                            44                                                           11                            24                                                     23                  28
  T. protein, g/dL            6.70--8.30     6.5                                   7                             6.99                          6.5                                                          6                             6.8                                                    6.6                 6.6
  Albumin, g/dL               4.00--5.00     3.22                                  ND                            3.23                          3.3                                                          3.5                           4.4                                                    4                   4.1
  Gamma-GTP, U/I              10--47         457                                   351                           181                           57                                                           109                           199                                                    187                 209
                                                                                                                                                                                                                                                                                                                     
  ALP, U/L                    115--359       1,086                                 973                           1,532                         793                                                          463                           469                                                    388                 367
  T. bilirubin, mg/dL         0.30--1.20     0.92                                  ND                            0.88                          1.20                                                         0.5                           0.7                                                    0.8                 1
  D. bilirubin, mg/dL         ≤0.60          0.27                                  ND                            0.21                          0.30                                                         0.1                           0.2                                                    0.2                 0.2
  T. cholesterol, mg/dL       128--219       110                                   124                           214                           150                                                          ND                            ND                                                     ND                  ND
  Hb, g/dL                    11.0--15.0     15.4                                  ND                            14.7                          14.9                                                         11.4                          15.6                                                   16.1                15.1
                                                                                                                                                                                                                                                                                                                     
  PLT, ×10^−4^/µL             13.0--36.0     9.9                                   ND                            5.3                           6.0                                                          12.1                          9.4                                                    13.7                11.4
  AFP, ng/mL                  ≤8.7           41.9                                  29.6                          215.7                         206.7                                                        ND                            3.0                                                    2                   2
  FT4, ng/dL                  0.88--1.56     ND                                    ND                            ND                            ND                                                           ND                            1.44                                                   0.64                1.01
  TSH, µIU/L                  0.210--3.850   ND                                    ND                            ND                            ND                                                           ND                            3.4                                                    30.36               10
                                                                                                                                                                                                                                                                                                                     
  FBS, mg/dL                  80--109        128                                   102                           82                            107                                                          ND                            ND                                                     ND                  ND
  HbA1c, %                    4.9--6.0       5                                     ND                            4.9                           ND                                                           ND                            5.8                                                    5.9                 5.9
  HCV viral load, logIU/mL                   6.8                                   6.9                           ND                            ND                                                           ND                            7.24                                                   Negative            Negative

T., total; D., direct; ND, not determined.
